2-[2-[1-[(2-Methylpropan-2-yl)oxycarbonyl]piperidin-4-yl]ethyl]propanedioic acid

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 2-[2-[1-[(2-Methylpropan-2-yl)oxycarbonyl]piperidin-4-yl]ethyl]propanedioic acid
• 化学式: C₁₅H₂₅NO₆
• 分子量: 315.36
• InChiKey: UHCLHBJWGLKMDJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  22
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  104
• 氢给体数：
  2
• 氢受体数：
  6

文献信息

• Phosphinyloxy, oxime and carboxylic acid derivatives which are useful as carboxypeptidase U inhibitors
  申请人：Linschoten Marcel

  公开号：US20060079484A1

  公开（公告）日：2006-04-13

  The present invention relates to compounds of Formula I, and pharmaceutically acceptable salts or solvates thereof, or solvates of such salts, which compounds inhibit carboxypeptidase U and thus can be used in the prevention and treatment of diseases associated with carboxypeptidase U. In further aspects, the invention relates to compounds of the invention for use in therapy; to processes for preparation of such new compounds; to pharmaceutical compositions containing at least one compound of the invention, or a pharmaceutically acceptable salt or solvate thereof, as active ingredient; and to the use of the active compounds in the manufacture of medicaments for the medical use indicated above.

  本发明涉及I式化合物及其药学上可接受的盐或溶剂，或这些盐的溶剂，这些化合物抑制羧肽酶U，因此可用于预防和治疗与羧肽酶U相关的疾病。此外，本发明还涉及用于治疗的本发明化合物；制备这些新化合物的过程；包含本发明化合物中至少一种作为活性成分的药物组合物；以及在制造上述医疗用途的药物中使用活性化合物。
• NEW COMPOUNDS
  申请人：AstraZeneca AB

  公开号：EP1180099A1

  公开（公告）日：2002-02-20
• US7354895B1
  申请人：——

  公开号：US7354895B1

  公开（公告）日：2008-04-08
• US7423012B2
  申请人：——

  公开号：US7423012B2

  公开（公告）日：2008-09-09
• [EN] NEW COMPOUNDS<br/>[FR] NOUVEAUX COMPOSES
  申请人：ASTRAZENECA AB

  公开号：WO2000066550A1

  公开（公告）日：2000-11-09

  The present invention relates to compounds of Formula (I), and pharmaceutically acceptable salts or solvates thereof, or solvates of such salts, which compounds inhibit carboxypeptidase U and thus can be used in the prevention and treatment of diseases associated with carboxypeptidase U. In further aspects, the invention relates to compounds of the invention for use in therapy; to processes for preparation of such new compounds; to pharmaceutical compositions containing at least one compound of the invention, or a pharmaceutically acceptable salt or solvate thereof, as active ingredient; and to the use of the active compounds in the manufacture of medicaments for the medical use indicated above.